nach oben

Erschienen in:

01.09.2012 | Original Article

Expression and Clinical Significance of UCH37 in Human Esophageal Squamous Cell Carcinoma

verfasst von: Yanjie Chen, Da Fu, Junjie Xi, Zongfei Ji, Taotao Liu, Yushui Ma, Yuan Zhao, Ling Dong, Qun Wang, Xizhong Shen

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Ubiquitin carboxyl-terminal hydrolase 37 (UCH37), a member of the DUBs, was found to play an important role in oncogenesis through promoting some Proto-oncogenes’ expression and stem cell-like characteristics in the cell in previous research. The aim of this study was to assess the value of UCH37 in predicting tumor recurrence after curative resection in esophageal squamous cell carcinoma (ESCC) patients.

Methods

We analyzed UCH37 protein expression in 111 clinicopathologically characterized ESCC cases, from those who underwent curative resection between 2007 and 2008, by immunohistochemistry. The prognostic significance was assessed using Kaplan–Meier survival estimates and log-rank tests.

Results

We found that UCH37 expression was higher in the cancer tissue than in non-tumorous control tissue at protein level and was overexpressed in tumor tissues of recurrent patients. There was a significant difference of UCH37 expression in patients categorized according to TNM stage (p = 0.038) and lymph nodes metastasis condition (p = 0.009). Univariate analyses revealed that UCH37 was a significant predictor for overall survival and disease-free survival, and multivariate analyses showed that UCH37 was an independent prognostic marker for ESCC recurrence. A prognostic significance of UCH37 was also found in the subgroup of lymph nodes metastasis condition classification. About 90 % of the recurrent patients recurred within 2 years, of which 84.4 % were predicted by UCH37.

Conclusion

UCH37 is associated with outcome and recurrence of ESCC and can be a novel predictor for poor prognosis of ESCC patients after curative resection.

Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–2150.PubMedCrossRef

Day NE, Varghese C. Oesophageal cancer. Cancer Surv. 1994;19–20:43–54.PubMed

Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol. 2002;37:1359–1365.PubMedCrossRef

Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus. 2006;19:425–432.PubMedCrossRef

Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–479.PubMedCrossRef

Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503–533.PubMedCrossRef

Finley D, Ciechanover A, Varshavsky A. Ubiquitin as a central cellular regulator. Cell. 2004;116:S29–S32.PubMedCrossRef

Sridhar VV, Kapoor A, Zhang K, Zhu J, et al. Control of DNA methylation and heterochromatic silencing by histone H2B deubiquitination. Nature. 2007;447:735–738.PubMedCrossRef

Liu H, Buus R, Clague MJ, Urbe S. Regulation of ErbB2 receptor status by the proteasomal DUB POH1. PLoS ONE. 2009;4:e5544.PubMedCrossRef

10.

Singhal S, Taylor MC, Baker RT. Deubiquitylating enzymes and disease. BMC Biochem. 2008;9:S3.PubMedCrossRef

11.

Yao T, Song L, Xu W, DeMartino GN, et al. Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat Cell Biol. 2006;8:994–1002.PubMedCrossRef

12.

Schreiner P, Chen X, Husnjak K, Randles L, et al. Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction. Nature. 2008;453:548–552.PubMedCrossRef

13.

Husnjak K, Elsasser S, Zhang N, Chen X, et al. Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature. 2008;453:481–488.PubMedCrossRef

14.

Hamazaki J, Iemura S, Natsume T, Yashiroda H, et al. A novel proteasome interacting protein recruits the deubiquitinating enzyme UCH37 to 26S proteasomes. EMBO J. 2006;25:4524–4536.PubMedCrossRef

15.

Qiu XB, Ouyang SY, Li CJ, Miao S, et al. hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37. EMBO J. 2006;25:5742–5753.PubMedCrossRef

16.

Wicks SJ, Haros K, Maillard M, Song L, et al. The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling. Oncogene. 2005;24:8080–8084.PubMedCrossRef

17.

Wicks SJ, Grocott T, Haros K, Maillard M, et al. Reversible ubiquitination regulates the Smad/TGF-beta signalling pathway. Biochem Soc Trans. 2006;34:761–763.PubMedCrossRef

18.

Cutts AJ, Soond SM, Powell S, Chantry A. Early phase TGFbeta receptor signalling dynamics stabilised by the deubiquitinase UCH37 promotes cell migratory responses. Int J Biochem Cell Biol. 2011;43:604–612.PubMedCrossRef

19.

Chen Z, Niu X, Li Z, Yu Y, et al. Effect of ubiquitin carboxy-terminal hydrolase 37 on apoptotic in A549 cells. Cell Biochem Funct. 2011;29:142–148.PubMedCrossRef

20.

Rolen U, Kobzeva V, Gasparjan N, Ovaa H, et al. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog. 2006;45:260–269.PubMedCrossRef

21.

Fang Y, Mu J, Ma Y, Ma D, et al. The interaction between ubiquitin C-terminal hydrolase 37 and glucose-regulated protein 78 in hepatocellular carcinoma. Mol Cell Biochem. 2012;359:59–66.PubMedCrossRef

22.

Kapuria V, Peterson LF, Fang D, Bornmann WG, et al. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 2010;70:9265–9276.PubMedCrossRef

23.

Al-Shami A, Jhaver KG, Vogel P, Wilkins C, et al. Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development. PLoS ONE. 2010;5:e13654.PubMedCrossRef

24.

Fang Y, Fu D, Shen XZ. The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim Biophys Acta. 2010;1806:1–6.PubMed

Titel: Expression and Clinical Significance of UCH37 in Human Esophageal Squamous Cell Carcinoma
verfasst von: Yanjie Chen
Da Fu
Junjie Xi
Zongfei Ji
Taotao Liu
Yushui Ma
Yuan Zhao
Ling Dong
Qun Wang
Xizhong Shen
Publikationsdatum: 01.09.2012
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 9/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-012-2181-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Expression and Clinical Significance of UCH37 in Human Esophageal Squamous Cell Carcinoma